Drug Trial Radar · NCT04649385
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Mar 4, 2021
Primary completion
Oct 17, 2025
Study completion May 15, 2026
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Dec 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
BGB-15025Drug
Administered orally once or twice daily (QD or BID)
TislelizumabDrug
Administered 200 mg intravenous (IV) infusion
CarboplatinDrug
Administered intravenously
CisplatinDrug
Administered intravenously
PemetrexedDrug
Administered intravenously
OxaliplatinDrug
Administered intravenously
CapecitabineDrug
Administered intravenously
PaclitaxelDrug
Administered intravenously
nab-paclitaxelDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 3 Years
- Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 4 Years
- Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 4 years
- The maximum tolerated dose (MTD) of BGB-15025Time frame: Up to 3 Years
- Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapyTime frame: Up to 3 years
- RDFE of BGB-15025 in combination with tislelizumabTime frame: Up to 3 years
- Phase 1b: Overall Response Rate (ORR) as assessed by the investigatorTime frame: Up to 2 years
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Icahn School of Medicine At Mount Sinai
New York, New York
The University of Texas Md Anderson Cancer Center
Houston, Texas
Ut Health San Antonio Mays Cancer Center
San Antonio, Texas
Prince of Wales Hospital
Randwick, New South Wales, Australia
Ashford Cancer Centre Research Northeast
Windsor Gardens, South Australia, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Auckland City Hospital
Auckland, New Zealand
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.